Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIHYDROERGOTAMINE MESYLATE vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydroergotamine mesylate is an ergot alkaloid with potent agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. It also has partial agonist/antagonist activity at alpha-adrenergic and dopamine receptors, contributing to its antimigraine effects.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Acute treatment of migraine headaches with or without aura (FDA-approved),Acute treatment of cluster headache episodes (off-label)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
1 mg intramuscularly or subcutaneously, repeat at 1-hour intervals as needed, maximum 3 mg per 24 hours and 6 mg per week; intravenous use is reserved for severe cases: 0.5-1 mg IV, may repeat once after 1 hour, maximum 2 mg per 24 hours.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal half-life is approximately 9 hours (range 7-13 hours) after IM administration; clinical effect duration corresponds to this elimination phase.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Primarily hepatic via CYP3A4; undergoes first-pass metabolism. The main metabolite is 8'-hydroxy-dihydroergotamine, which is also active.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily hepatic metabolism; <10% excreted unchanged in urine; biliary/fecal excretion accounts for ~90% of metabolites.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Approximately 93% bound, primarily to serum albumin and alpha-1-acid glycoprotein.
Low protein binding; 0–11% bound, primarily to albumin.
Approximately 0.25-0.3 L/kg; indicates moderate tissue distribution with high affinity for vascular receptors.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intramuscular: ~30-40% (due to first-pass metabolism); intranasal: ~38-50% (relative to IM); oral: <1% (not clinically used orally).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: use with caution, reduce dose by 50%; Cr Cl >60 m L/min: no adjustment needed.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B: contraindicated; Child-Pugh Class C: contraindicated.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Not recommended for patients under 12 years of age due to lack of safety data; for adolescents (12-17 years): 0.5-1 mg subcutaneously or intramuscularly, repeat at 1-hour intervals as needed, maximum 2 mg per 24 hours and 4 mg per week.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Elderly patients may have increased sensitivity; initiate at 0.5 mg intramuscularly or subcutaneously, maximum 2 mg per 24 hours; monitor for adverse effects (e.g., vasospasm, ischemia).
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors (including protease inhibitors, azole antifungals, and macrolide antibiotics).
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of cerebral and peripheral vasospasm, especially with prolonged use or overdose,May cause ergotism (symptoms include numbness, tingling, cyanosis, and gangrene),Caution in patients with hypertension, coronary artery disease, or impaired hepatic/renal function,Avoid repeated administration within 24 hours due to risk of accumulation and toxicity
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Concurrent use with potent CYP3A4 inhibitors (e.g., protease inhibitors, azole antifungals, macrolides),Uncontrolled hypertension,Coronary artery disease, including angina or history of myocardial infarction,Peripheral vascular disease,Sepsis,Pregnancy (category X),Severe hepatic or renal impairment,History of hemiplegic or basilar migraine (due to risk of vasospasm)
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Grapefruit juice may increase systemic exposure; avoid concurrent consumption. Alcohol may exacerbate headache or adverse effects.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
FDA Pregnancy Category X. Dihydroergotamine is contraindicated in all trimesters due to oxytocic effects and uterine hypertonicity risk. Case reports of fetal hypoxia, growth restriction, and malformations (including limb defects and neural tube defects) from ergot alkaloids. First trimester: increased risk of spontaneous abortion and congenital anomalies. Second and third trimesters: risk of preterm labor, fetal distress, and low birth weight due to uteroplacental insufficiency.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Contraindicated in breastfeeding. Dihydroergotamine is excreted in breast milk; M/P ratio unknown. Ergot alkaloids can cause vomiting, diarrhea, weak pulse, unstable blood pressure, and convulsions in infants. May also suppress lactation via prolactin inhibition.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Not applicable; contraindicated in pregnancy. No pharmacokinetic studies exist due to safety concerns. No dose adjustments are recommended as the drug should not be used.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Avoid use within 24 hours of other ergot alkaloids or triptans due to additive vasospasm risk. Administer at first sign of migraine aura or headache; may repeat after 1 hour (max 3 mg/day, 6 mg/week). Contraindicated in coronary artery disease, uncontrolled hypertension, and pregnancy. Intranasal route may cause rhinorrhea or nasal congestion.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Use exactly as prescribed at the first sign of a migraine headache.,Do not exceed 3 mg in 24 hours or 6 mg in one week.,Seek emergency help if you experience signs of ergotism: severe muscle pain, cold or numb fingers/toes, or chest tightness.,Avoid grapefruit juice as it may increase drug levels.,Do not take with other migraine medications (triptans, other ergots) within 24 hours.,Report any chest pain, shortness of breath, or irregular heartbeat immediately.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Dihydroergotamine is a potent inhibitor of CYP3A4, the primary enzyme responsible for the metabolism of bortezomib. Co-administration can significantly decrease bortezomib clearance, leading to elevated plasma concentrations and increased risk of bortezomib-related toxicities, particularly peripheral neuropathy, thrombocytopenia, and hypotension. Clinicians should monitor for enhanced adverse effects and consider dose adjustments or alternative therapies."
"Seratrodast, a thromboxane A2 receptor antagonist, inhibits CYP3A4-mediated metabolism of dihydroergotamine, a vasoconstrictor ergot alkaloid. This results in elevated plasma dihydroergotamine concentrations, increasing the risk of ergotism (severe vasospasm, ischemia, and potential gangrene). Clinical outcomes may include hypertension, myocardial ischemia, and peripheral vascular compromise, particularly in patients with risk factors such as coronary artery disease or smoking."
"Dexchlorpheniramine maleate, a first-generation antihistamine with significant anticholinergic properties, may inhibit the metabolism of dihydroergotamine via competitive antagonism of cytochrome P450 (CYP) 3A4 isoenzymes. This interaction can lead to elevated plasma concentrations of dihydroergotamine, increasing the risk of ergotism (e.g., vasospasm, ischemia, gangrene) and hypertensive crisis. Clinically, patients may present with peripheral coldness, muscle pain, cyanosis, or severe hypertension, particularly with concurrent use or overdose."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIHYDROERGOTAMINE MESYLATE vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DIHYDROERGOTAMINE MESYLATE is a Ergot Alkaloid that works by Dihydroergotamine mesylate is an ergot alkaloid with potent agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. It also has partial agonist/antagonist activity at alpha-adrenergic and dopamine receptors, contributing to its antimigraine effects.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIHYDROERGOTAMINE MESYLATE and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIHYDROERGOTAMINE MESYLATE is: 1 mg intramuscularly or subcutaneously, repeat at 1-hour intervals as needed, maximum 3 mg per 24 hours and 6 mg per week; intravenous use is reserved for severe cases: 0.5-1 mg IV, may repeat once after 1 hour, maximum 2 mg per 24 hours.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIHYDROERGOTAMINE MESYLATE and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIHYDROERGOTAMINE MESYLATE is classified as Category D/X. FDA Pregnancy Category X. Dihydroergotamine is contraindicated in all trimesters due to oxytocic effects and uterine hypertonicity risk. Case reports of fetal hypoxia, growth restr. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.